LyondellBasell
LYB
$63.47
-2.58%
LyondellBasell Industries N.V. is a global petrochemical producer, operating in the United States, Europe, and Asia, with core products including polypropylene, polyethylene, and propylene oxide used in a wide array of consumer and industrial goods. The company is a market leader, notably the world's largest producer of polypropylene, leveraging its integrated operations and scale to compete in the cyclical chemicals industry. The current investor narrative is dominated by severe industry headwinds, as evidenced by a recent dividend cut described as a response to 'one of the longest downturns in the chemical industry,' and heightened volatility tied to geopolitical events impacting key feedstock supplies like naphtha.…
LYB
LyondellBasell
$63.47
Related headlines
Investment Opinion: Should I buy LYB Today?
Rating: Hold. The core thesis is that LYB is a deeply cyclical stock at a potentially attractive entry point in its cycle, but the timing of the recovery remains too uncertain to warrant a Buy rating, given the severe ongoing fundamental pressure.
The stock trades at a deeply discounted Price-to-Sales ratio of 0.46, suggesting most bad news is priced in. Analyst forward EPS estimates average $7.21, implying a forward P/E of 8.8, which is cheap for a market leader if earnings materialize. However, current fundamentals are dire, with Q4 revenue down -25.3% YoY and gross margins at 6.49%. The robust TTM free cash flow of $2.26 billion and solid current ratio of 1.77 provide a financial cushion, but negative ROE of -7.37% shows the business is not currently creating value.
The two biggest risks are a further prolongation of the industry downturn, crushing margins, and a failure of earnings to recover towards the $7+ EPS estimate range. This Hold would upgrade to a Buy if quarterly gross margins show sequential improvement back above 10% or if the forward P/E compresses below 7x on sustained positive earnings revisions. It would downgrade to a Sell if quarterly revenue declines accelerate further or if free cash flow turns negative. Relative to its own history and the sector's challenged outlook, the stock is fairly valued—it is cheap for a reason, not undervalued.
Sign up to view all
LYB 12-Month Price Forecast
LYB presents a high-risk, high-potential-reward scenario typical of deep cyclicals. The valuation is compelling and suggests significant upside if the cycle turns, supported by the company's scale and cash generation. However, the fundamental deterioration is severe and recent, with no clear visibility on the timing of a recovery. The neutral stance reflects this balance: the risk of further downside from current levels is real if the downturn persists, but the potential reward for patient, risk-tolerant investors is substantial. The stance would upgrade to bullish on concrete evidence of margin stabilization (e.g., two consecutive quarters of gross margin expansion) or downgrade to bearish on a breakdown below key technical support at $60 accompanied by worsening fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on LyondellBasell's 12-month outlook, with a consensus price target around $82.51 and implied upside of +30.0% versus the current price.
Average Target
$82.51
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$51 - $83
Analyst target range
Analyst coverage consists of 10 firms, with recent institutional ratings showing a mix of Hold/Neutral and a few upgrades to Buy/Outperform in March 2026, suggesting a cautiously improving sentiment from a very low base. The consensus appears neutral-to-cautious, with targets implying significant uncertainty; however, specific average target price and implied upside data are not available in the provided dataset, limiting a precise consensus calculation. The wide range in estimated EPS for the forward period, from a low of $4.56 to a high of $9.62, underscores the high degree of uncertainty regarding the pace and magnitude of an earnings recovery, with the low end reflecting a continuation of current pressures and the high end anticipating a sharp cyclical rebound.
Bulls vs Bears: LYB Investment Factors
The investment debate for LYB is a classic battle between deep cyclical value and severe fundamental deterioration. The bull case, currently supported by stronger evidence, rests on a historically cheap valuation (PS of 0.46), robust underlying cash flow ($2.26B TTM FCF), and a balance sheet capable of weathering the storm. The bear case highlights the alarming pace of revenue decline (-25.3% YoY), collapsing margins (6.49% gross), and management's own dire assessment of the industry downturn, as evidenced by the dividend cut. The single most important tension is the timing and magnitude of the cyclical recovery in chemical margins. If the downturn persists longer than the market's discounted valuation assumes, LYB risks becoming a value trap. Conversely, any early sign of margin stabilization could trigger a powerful re-rating from deeply depressed levels.
Bullish
- Deeply Discounted Valuation: The stock trades at a trailing Price-to-Sales ratio of 0.46, near the bottom of its multi-year historical range and representing a significant discount to typical chemical industry valuations. This low multiple prices in extreme pessimism and offers a substantial margin of safety if the cyclical downturn proves less severe or shorter than feared.
- Strong Free Cash Flow Generation: Despite operational losses, the company generated a robust $2.26 billion in trailing twelve-month free cash flow. This cash generation provides financial flexibility to weather the downturn, support the balance sheet, and potentially return capital to shareholders once profitability is restored.
- Solid Balance Sheet & Liquidity: The company maintains a current ratio of 1.77, indicating adequate short-term liquidity, and a moderate debt-to-equity ratio of 1.58. This financial stability is a critical advantage during a prolonged industry downturn, reducing the risk of a liquidity crisis.
- Technical Recovery from Trough: The stock has staged a significant recovery from its 52-week low of $41.58, posting a 52-week gain of +18.16% and a 6-month surge of +52.66%. This price action suggests the market may have already priced in the worst of the downturn, with the recent pullback potentially offering a better entry point.
Bearish
- Severe Revenue & Margin Contraction: Q4 2025 revenue declined -25.3% YoY to $7.09B, with gross margin collapsing to 6.49% from 15.12% a year earlier. This dramatic deterioration reflects intense cyclical headwinds and overcapacity, directly pressuring the bottom line into a net loss of -$140 million for the quarter.
- Dividend Cut Signals Prolonged Downturn: Management's decision to slash the dividend, described as a response to 'one of the longest downturns in the chemical industry,' is a clear signal of fundamental distress and limited near-term cash return visibility. This action erodes a key pillar of the investment thesis for income-oriented shareholders.
- Negative Profitability Metrics: The company reports a negative Return on Equity of -7.37% and a negative net margin of -2.46%, indicating it is currently destroying shareholder value. Until operating income turns sustainably positive, the stock remains a 'show me' story reliant on a future cyclical rebound.
- High Geopolitical & Supply Chain Volatility: Recent news highlights severe naphtha supply disruptions in the Middle East, a key feedstock, directly threatening production costs and output. While the Strait of Hormuz reopening eased some pressure, the stock remains highly sensitive to unpredictable geopolitical events impacting commodity inputs.
LYB Technical Analysis
The stock is in a volatile recovery phase from a deep trough, having posted a 52-week price change of +18.16% but currently trading in a corrective pullback. The current price of $66.18 sits approximately 21% above its 52-week low of $41.58 but also 21% below its 52-week high of $83.94, positioning it in the lower-middle of its annual range, suggesting the momentum from the initial recovery has faded. Recent momentum has turned sharply negative, with a 1-month decline of -14.89% and a 3-month drop of -1.39%, which starkly diverges from the positive 6-month gain of +52.66%; this deceleration signals a significant loss of bullish momentum and potential exhaustion of the prior uptrend. Key technical support is anchored at the 52-week low of $41.58, while immediate overhead resistance is at the recent high of $83.94; a breakdown below the recent lows near $66 could signal a retest of deeper support, while a breakout above $84 would require a major catalyst. The stock's beta of 0.355 indicates it is significantly less volatile than the broader market, which, combined with a maximum drawdown of -37.1%, suggests it can still experience sharp declines despite its lower relative volatility.
Beta
0.33
0.33x market volatility
Max Drawdown
-37.1%
Largest decline past year
52-Week Range
$42-$84
Price range past year
Annual Return
+3.8%
Cumulative gain past year
| Period | LYB Return | S&P 500 |
|---|---|---|
| 1m | -14.6% | -0.1% |
| 3m | -12.2% | +11.4% |
| 6m | +43.0% | +8.2% |
| 1y | +3.8% | +22.7% |
| ytd | +43.0% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LYB Fundamental Analysis
Revenue is under significant pressure, with Q4 2025 revenue of $7.09 billion representing a -25.33% year-over-year decline, continuing a trend of sequential quarterly revenue decreases from $7.77 billion in Q1 2025; this steep contraction reflects severe cyclical headwinds in the chemical industry. The company is currently unprofitable on a net income basis, posting a Q4 2025 net loss of -$140 million and a gross margin of only 6.49%, which is a severe compression from the 15.12% gross margin reported in Q3 2024; margins have deteriorated dramatically, with operating income turning negative at -$40 million in the latest quarter compared to positive $865 million a year earlier. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.58, but cash generation remains a mixed signal: trailing twelve-month free cash flow is a robust $2.26 billion, yet the current ratio of 1.77 indicates adequate short-term liquidity, and the negative Return on Equity of -7.37% highlights the current strain on shareholder returns from operational losses.
Quarterly Revenue
$7.1B
2025-12
Revenue YoY Growth
-0.25%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$2.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LYB Overvalued?
Given the negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.46, while the forward-looking valuation can be inferred from the estimated revenue; this low multiple reflects the market's discount for a company in a severe downturn with compressed margins. Compared to typical chemical industry valuations, a PS ratio below 0.5 represents a deep discount, often signaling expectations of continued revenue pressure or poor profitability, though it may also price in a cyclical bottom. Historically, the stock's own PS ratio has fluctuated widely, from a high above 4.0 in early 2021 to the current 0.46; trading near the bottom of its multi-year historical range suggests the market is pricing in a deeply pessimistic scenario, which could indicate a value opportunity if fundamentals stabilize, but also carries the risk of value trap if the downturn persists.
PE
-18.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -25x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute and center on collapsing profitability. The gross margin of 6.49% in Q4 2025 is unsustainable and, if it persists, will continue to drive net losses, as seen in the -$140 million quarterly result. The negative ROE of -7.37% indicates the business is currently eroding capital. While free cash flow remains positive, this is largely due to non-cash charges; a prolonged downturn could pressure this metric. Revenue concentration in cyclical petrochemicals leaves no natural hedge, making earnings highly volatile and dependent on a global economic rebound.
Market & Competitive Risks include valuation compression if the 'value' thesis fails to materialize. The stock's low beta of 0.355 suggests it is less correlated to the broad market, but its -37.1% maximum drawdown shows it can experience sharp, idiosyncratic declines tied to its industry cycle. Competitive risks are heightened by global overcapacity in key products like polypropylene and polyethylene, which prolongs the margin squeeze. Regulatory and environmental pressures on the chemicals sector add long-term cost and capex burdens. The recent news flow underscores extreme sensitivity to feedstock supply shocks, a persistent macro risk.
Worst-Case Scenario involves the chemical downturn extending beyond 2026, leading to consecutive quarters of losses that deplete cash reserves and force further balance sheet deterioration. In this scenario, the dividend cut is followed by additional guidance reductions, triggering a loss of investor confidence. The stock could retest its 52-week low of $41.58, representing a potential downside of approximately -37% from the current price of $66.18. A breach of this level could see the stock fall towards its pandemic-era lows, implying a total loss in the -40% to -50% range from current levels if the company's financial stability comes into question.
FAQ
The primary risk is a prolonged industry downturn crushing profitability, evidenced by the Q4 2025 gross margin of only 6.49%. Competitive and overcapacity risks are high, delaying any margin recovery. Geopolitical volatility directly impacts key feedstock supplies like naphtha, creating unpredictable cost spikes, as recent Middle East news highlighted. Financial risk, while mitigated by strong TTM FCF of $2.26B, includes the potential for further erosion of shareholder returns if losses continue, as shown by the negative -7.37% ROE and the recent dividend cut.
The 12-month outlook is highly uncertain, centered on three scenarios. The Base Case (50% probability) sees the stock trading between $65 and $80 as the downturn bottoms. The Bull Case (30% probability), driven by a sharp cyclical rebound, targets $83 to $95. The Bear Case (20% probability), involving a deepening slump, risks a fall to $42-$55, retesting the 52-week low. The most likely scenario is the Base Case, assuming the severe pressures of the last year begin to stabilize but a full recovery remains elusive.
LYB is fairly valued relative to its current distressed fundamentals but historically undervalued relative to its own cycle. The trailing PS ratio of 0.46 is near the bottom of its multi-year range and represents a deep discount to the sector, reflecting the severe margin compression and losses. The forward P/E of 8.8, based on analyst EPS estimates of $7.21, is cheap but hinges entirely on a earnings recovery that is not yet visible. The market is pricing in a prolonged downturn; the stock is cheap for a reason, not obviously undervalued without a cyclical catalyst.
LYB is a speculative buy only for investors with a high risk tolerance and a long-term horizon who believe the chemical cycle is near a bottom. At a Price-to-Sales ratio of 0.46, it is priced for continued distress, offering significant upside if the cycle turns. However, with revenue down -25.3% YoY and the company posting a net loss, it is a 'show me' story with real risk of further downside, potentially to its 52-week low of $41.58 (-37%). It is not a good buy for conservative or income-focused investors.
LYB is strictly a long-term, cyclical investment with a minimum horizon of 2-3 years to allow for the industry cycle to potentially turn. Its low beta of 0.355 and high fundamental volatility make it a poor short-term trading vehicle, as price moves will be driven by infrequent earnings reports and industry data points rather than daily market sentiment. The elimination of a reliable dividend further removes any short-term income rationale. Only investors willing to endure potential further volatility for a eventual cyclical payoff should consider it.